Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders

Can adjunctive semaglutide improve glycemic control and weight outcomes in individuals with early-stage prediabetes or diabetes and schizophrenia spectrum disorders who initiated clozapine or olanzapine within the past 5 years?In this randomized clinical trial including 73 participants, semaglutide was found to significantly reduce hemoglobin A level and body weight over a 26-week period. Approximately one-half of individuals treated with semaglutide achieved low-risk hemoglobin A levels, compared with the placebo group.This study found that semaglutide can mitigate the early metabolic burden associated with second-generation antipsychotic use in schizophrenia and may support the prevention of long-term cardiometabolic complications when initiated during the early stages of metabolic dysregulation.

Corresponding Author: Anders Fink-Jensen, DMSci, Psychiatric Centre Copenhagen, Hovedvejen 17, 1st Floor, 2000 Frederiksberg, Denmark (anders.fink-jensen@regionh.dk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.